株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙SALE
市場調査レポート

アトピー性皮膚炎治療薬の世界市場:2017〜2021年

Global Atopic Dermatitis Drugs Market 2017-2021

発行 TechNavio (Infiniti Research Ltd.) 商品コード 439477
出版日 ページ情報 英文 68 Pages
即納可能
価格
本日の銀行送金レート: 1USD=110.53円で換算しております。
Back to Top
アトピー性皮膚炎治療薬の世界市場:2017〜2021年 Global Atopic Dermatitis Drugs Market 2017-2021
出版日: 2017年01月24日 ページ情報: 英文 68 Pages
概要

アトピー性皮膚炎は主に子供に発症する一般的な慢性、再発型炎症性疾患です。アトピー性皮膚炎は世界的に罹患率が上昇しています。世界のアトピー性皮膚炎治療薬市場は2017〜2021年にかけCAGR4.20%で拡大すると予測されています。

当レポートでは、世界のアトピー性皮膚炎治療薬市場について調査し、市場の動向と2021年までの成長見通し、投与ルート別、地域別動向、および主要ベンダーのプロファイルなどをまとめています。

第1章 エグゼクティブサマリー

第2章 当レポートの範囲

第3章 調査方法

第4章 イントロダクション

第5章 アトピー性皮膚炎の概要

第6章 パイプライン分析

第7章 市況

  • 市場概要
  • 市場規模と予測

第8章 ファイブフォース分析

第9章 投与ルート別市場セグメンテーション

  • 経口
  • 局所
  • 注射

第10章 地域別セグメンテーション

  • 南北アメリカ
  • 欧州・中東・アフリカ
  • アジア太平洋地域

第11章 市場促進因子

  • アトピー性皮膚炎を悪化させる食物アレルギーの罹患率上昇
  • 全身性治療への注目
  • 途上国における薬理学製品の使用拡大

第12章 促進因子の影響

第13章 市場の課題

第14章 促進因子と課題の影響

第15章 市場動向

第16章 ベンダー環境

  • 競合シナリオ
  • LEO Pharma
  • Mylan
  • Valeant
  • Bayer HealthCare
  • Encore Dermatology

第17章 付録

第18章 Technavioについて

図表

図表
  • Exhibit 01: Global atopic dermatitis drugs market: Key customer segments
  • Exhibit 02: Pipeline analysis by phase 2016
  • Exhibit 03: Key pipeline molecules
  • Exhibit 04: Global atopic dermatitis drugs market: Snapshot
  • Exhibit 05: Global atopic dermatitis drugs market 2016-2021 ($ millions)
  • Exhibit 06: Global atopic dermatitis drugs market: Opportunity analysis
  • Exhibit 07: Five force analysis
  • Exhibit 08: Global atopic dermatitis drug market by ROA 2016
  • Exhibit 09: Oral ROA for atopic dermatitis
  • Exhibit 10: Global atopic dermatitis drugs market by geography 2016
  • Exhibit 11: Global atopic dermatitis drugs market by geography 2021
  • Exhibit 12: Market scenario: Americas
  • Exhibit 13: Atopic dermatitis drugs market in Americas 2016-2021 ($ millions)
  • Exhibit 14: Market scenario: EMEA
  • Exhibit 15: Atopic dermatitis drugs market in EMEA 2016-2021 ($ millions)
  • Exhibit 16: Market scenario in APAC
  • Exhibit 17: Atopic dermatitis drugs market in APAC 2016-2021 ($ millions)
  • Exhibit 18: Systemic therapy for atopic dermatitis.
  • Exhibit 19: Impact of drivers
  • Exhibit 20: Impact of drivers and challenges
  • Exhibit 21: New and emerging treatments for atopic dermatitis: Agents in Phase II clinical trials.
  • Exhibit 22: Global atopic dermatitis drugs market: Competitive structure analysis 2016
  • Exhibit 23: Competitive analysis of global atopic dermatitis drugs market
  • Exhibit 24: Market penetration of vendors in global atopic dermatitis drug market 2016
  • Exhibit 25: LEO Pharma: Key highlights
  • Exhibit 26: LEO Pharma: Strength assessment
  • Exhibit 27: LEO Pharma: Strategy assessment
  • Exhibit 28: LEO Pharma: Opportunity assessment
  • Exhibit 29: LEO Pharma: YoY revenue and growth rate of Protopic 2014-2016 ($ million)
  • Exhibit 30: Mylan: Key highlights
  • Exhibit 31: Mylan: Strength assessment
  • Exhibit 32: Mylan: Strategy assessment
  • Exhibit 33: Mylan: Opportunity assessment
  • Exhibit 34: Valeant: Key highlights
  • Exhibit 35: Valeant: Strength assessment
  • Exhibit 36: Valeant: Strategy assessment
  • Exhibit 37: Valeant: Opportunity assessment
  • Exhibit 38: Bayer HealthCare: Key highlights
  • Exhibit 39: Bayer HealthCare: Strength assessment
  • Exhibit 40: Bayer HealthCare: Strategy assessment
  • Exhibit 41: Bayer HealthCare: Opportunity assessment
  • Exhibit 42: Encore Dermatology: Key highlights
  • Exhibit 43: Encore Dermatology: Strength assessment
  • Exhibit 44: Encore Dermatology: Strategy assessment
目次
Product Code: IRTNTR11179

About Atopic Dermatitis Drugs

Atopic dermatitis is a common, chronic, relapsing, inflammatory disease that primarily affects young children. Atopy refers to an inherited tendency to produce IgE antibodies, whereas, dermatitis means inflammation of the skin. Atopic dermatitis is associated with asthma, inhalant allergies (hay fever), and chronic dermatitis. In this condition, the skin becomes extremely itchy and inflamed, which causes redness, cracking, weeping, swelling, vesicle formation, crushing, and scaling. Atopic dermatitis is very common worldwide, and its prevalence rate is increasing. The data estimates suggest that nearly 60% of the patients develop symptoms in the first year of life, and 88%-92% develop symptoms before the age of five.

Technavio's analysts forecast the global atopic dermatitis drugs market to grow at a CAGR of 4.20% during the period 2017-2021.

Covered in this report

The report covers the present scenario and the growth prospects of the global atopic dermatitis drugs market for 2017-2021. To calculate the market size, the report considers the revenue generated from the sales of atopic dermatitis drugs.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA

Technavio's report, Global Atopic Dermatitis Drugs Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • LEO Pharma
  • Mylan
  • Valeant
  • Bayer HealthCare
  • Encore Dermatology

Market driver

  • Growing prevalence of food allergies exacerbating atopic dermatitis
  • For a full, detailed list, view our report

Market challenge

  • Poor patient adherence due to inadequate information on drug usage
  • For a full, detailed list, view our report

Market trend

  • Increasing M&A leading to market consolidation
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2021 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of our procurement specialist's time when you purchase this market report. Details are provided within the report.

Table of Contents

PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction

  • Key market highlights

PART 05: An overview of atopic dermatitis

PART 06: Pipeline analysis

PART 07: Market landscape

  • Market overview
  • Market size and forecast

PART 08: Five force analysis

PART 09: Market segment by ROA

  • Oral ROA
  • Topical ROA
  • Injectable ROA

PART 10: Geographical segmentation

  • Atopic dermatitis drugs market in Americas
  • Atopic dermatitis drug market in EMEA
  • Atopic dermatitis drugs market in APAC

PART 11: Market drivers

  • Growing prevalence of food allergies exacerbating atopic dermatitis
  • Growing focus on systemic therapies
  • Increasing use of pharmacological products in developing countries

PART 12: Impact of drivers

PART 13: Market challenges

  • Black box warning for Elidel and Protopic
  • Highly genericized market
  • Poor patient adherence due to inadequate information on drug usage

PART 14: Impact of drivers and challenges

PART 15: Market trends

  • Increasing M&A leading to market consolidation
  • Launch of first biologic for atopic dermatitis
  • Growing focus on novel drugs

PART 16: Vendor landscape

  • Competitive scenario
  • LEO Pharma
  • Mylan
  • Valeant
  • Bayer HealthCare
  • Encore Dermatology

PART 17: Appendix

  • List of abbreviations

PART 18: Explore Technavio

Back to Top